The combination of electronics, materials science and information technologies, and the application of micro and nanotechnologies for the development of innovative sensors and cutting-edge devices, are radically changing the future of biomedicine towards new challenges and new frontiers.

The biomedical division of Optoi develops optical devices for diagnostic and therapeutic applications.

The Group employs a multidisciplinary team to create innovative solutions aimed at simplifying and making the detection of circulating biomolecules more reliable, providing valid support to medical staff and biopharmaceuticals. Optoi collaborates with local, national and international research bodies and is involved in several projects at European level.



•    EU funding H2020-MSCA-RISE-2020. Acronym: diaRNAgnosis. Title: A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids. Consortium leader: DGSL (Spain). GA No 101007934.
An international consortium, led by DESTINA Genomica S.L., combines transversal skills of companies and universities from Spain, Italy and the Netherlands.
The diaRNAgnosis project aims to create reliable and selective diagnostic tools for the detection of circulating cell-free (ccf) RNA in liquid biopsy samples of prostate cancer and germ cell tumours in the testicles.


  • CARITRO FOUNDATION. An innovative diagnostic device for the measurement of microRNAs in liquid biopsies. Consortium leader: University of Trento – CIBIO (Italy).

Optoi has been actively collaborating with the University of Trento - CIBIO for a few years. Thanks to this project, CIBIO, together with the Healthcare Trust of the Autonomous Province of Trento (APSS), will analyse microRNAs as potential predictors of the efficacy of abiraterone in patients with prostate cancer using conventional analytical systems and optical sensors developed by Optoi.

  • EU funding H2020-SC1-BHC-2018-2020. Acronym: ARREST-TB. Title: Accurate, Rapid, Robust and Economical diagnostic technologies for Tuberculosis. Consortium leader: The University of Edinburgh (UK). GA No 825931.

Optoi forms part of an international consortium, led by the University of Edinburgh, of universities and companies in Italy, the United Kingdom and Spain, and is dedicated to the development of diagnostic technologies for tuberculosis, in collaboration with the Research Institute of Tuberculosis in Moscow and with two other reference centres in India that deal with clinical validation.
The ARREST-TB (Accurate, Rapid, Robust and Economical diagnoStic Technologies for Tuberculosis) project aims to develop innovative technologies that can contribute to the early diagnosis of tuberculosis with trials in India and Russia.
Optoi - with its partner DESTINA Genomica - develops an innovative diagnostic system based on optoelectronic sensors and selective chemistry, measuring new generation biomarkers - microRNA - for the early diagnosis and therapeutic monitoring of Tuberculosis.


  • EU funding H2020 Marie-Curie Actions. Acronym: miRNA-DisEASY. Title: microRNA biomarkers in an innovative biophotonic sensor kit for high-specific diagnosis. Consortium leader: OPTOI Srl. (Italy). GA No 690866.

A multidisciplinary and intersectoral consortium led by Optoi, has synergistically involved companies and academic institutions in Germany, Spain, Italy and Brazil with reciprocal exchange of highly qualified personnel. The research has generated a stimulating scientific and technological environment, preparatory to the generation of new ideas and new technological solutions in the field of lung cancer diagnosis.

As part of the miRNA-DisEASY project, Optoi has developed a device alongside revolutionary chemical technology intended to simplify and make the detection of circulating biomarkers more reliable, providing valuable support to medical staff.
At the end of the project, OPTOI was awarded the title “key innovators” by “Innovation Radar”, a European Commission initiative.


  • E Garcia-Fernandez, et. al. miR-122 direct detection in human serum by time-gated fluorescence imaging. Chemical Communications, 2019, 55 (99), 14958-14961. 
  • S Detassis, et. al. New Platform for the Direct Profiling of microRNAs in Biofluids. Analytical Chemistry, 2019, 91 (9), 5874-5880. 
  • S Detassis, et. al. New Platform for the Direct Profiling of microRNAs in Biofluids. Best Poster Award at the Oligonucleotide Therapeutic Society annual meeting, 201